key: cord-0835267-vot3u36f
authors: Kumar, M.; Gulati, S.; Ansari, A. H.; Phutela, R.; Acharya, S.; Kathpalia, P.; Kanakan, A.; Maurya, R.; Vasudevan, J. S.; Murali, A.; Pandey, R.; Maiti, S.; Chakraborty, D.
title: RAY: CRISPR diagnostic for rapid and accurate detection of SARS-CoV2 variants on a paper strip
date: 2021-02-03
journal: nan
DOI: 10.1101/2021.02.01.21250900
sha: 178378d64199479602ff3071dbe50acdecd65e6f
doc_id: 835267
cord_uid: vot3u36f

The COVID-19 pandemic originating in the Wuhan province of China in late 2019 has impacted global health, causing increased mortality among elderly patients and individuals with comorbid conditions. During the passage of the virus through affected populations, it has undergone mutations- some of which have recently been linked with increased viral load and prognostic complexities. Interestingly, several of these variants are point mutations that are difficult to diagnose using the gold standard quantitative real-time PCR (qPCR) method. This necessitates widespread sequencing which is expensive, has long turn-around times, and requires high viral load for calling mutations accurately. In this study, we show that the high specificity of Francisella novicida Cas9 (FnCas9) to point mismatches can be successfully adapted for the simultaneous detection of SARS-CoV2 infection as well as for detecting point mutations in the sequence of the virus obtained from patient samples. We report the detection of the mutation N501Y (earlier shown to be present in the British N501Y.V1, South African N501Y.V2, and Brazilian N501Y.V3 variants of SARS-CoV2) within an hour using paper strip chemistry. The results were corroborated using deep sequencing. Our design principle can be rapidly adapted for other mutations, highlighting the advantages of quick optimization and roll-out of CRISPR diagnostics (CRISPRDx) for disease surveillance even beyond COVID-19.

, respectively) that have also been associated with a higher viral load in preliminary studies [8] [9] [10] . As air travel has resumed in most countries post lockdown, infected individuals harboring these mutations have instantly been detected in countries far away from their origin, generating concerns about greater disease incidence unless these cases are recognized and isolated. This is particularly important as vaccine roll-out has been initiated in several countries, and the studies about vaccine efficacy against the new variants are only in their infancy 11 .

Among the diagnostic methods that have been employed for identifying positive coronavirus cases, qPCR has been the most widely adopted nucleic acid-based test due to its ability to identify even low copy numbers of viral RNA in patient samples and has been considered as a gold standard in diagnosis [12] [13] [14] . However, probe-based qRT PCR assays rely on amplification of a target gene with real-time analysis of DNA copy numbers and are not suited for genotyping point mutations associated with novel CoV2 variants [15] [16] [17] [18] . Although strategies such as Amplification Refractory Mutation System-quantitative PCR (ARMS-qPCR) have been described in the literature for genotyping mutations in nucleic acids, these require substantial design and validation for reproducible readouts and hence are not routinely used for clinical diagnosis 19, 20 . Similarly, antigen-based SARS CoV2 assays which have lower sensitivity than qPCR have not yet been reported to specifically identify mutant variants. In the absence of any true diagnostic test for the variants, most countries have resorted to next-generation sequencing of patient sampleswhich greatly increases both the time and cost for identifying positive individuals [21] [22] [23] [24] .

We and several others have documented the applicability of CRISPR diagnostics (CRISPRDx) for identifying CoV2 signatures in patient samples [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Using the Cas9 from Francisella novicida (FnCas9) we have recently reported the development of the FELUDA (FnCas9 Editor Linked Uniform Detection Assay) platform for SARS-CoV2 diagnosis with similar accuracy as the gold standard qPCR test 25 . In this report, we introduce RAY (Rapid variant AssaY), an advancement of the FELUDA platform to identify mutational signatures of the coronavirus variants in a sample eliminating the need for sequencing.

RAY can successfully detect both the infection as well as the presence of the common N501Y mutation present across all the three new variants and distinguish it from the parent CoV2 lineage. Thus it can be employed as a primary surveillance method for isolating cases belonging to these groups and can enable the initiation of appropriate management protocols.

To develop RAY for SARS-CoV2 variant identification, we first analyzed the mutations arising in the three variant lineages reported from the UK, South Africa, and Brazil and looked for the accessibility to FnCas9 enzyme based on the presence of an NGG PAM site in the vicinity 37 . In an earlier study, we had successfully established that FnCas9 is unable to bind or cleave targets having two mismatches -in the 2nd and 6th position (PAM proximal) of the sgRNA-with respect to the target ( Figure 1A ) 25, 38 . Besides these, we had also systematically identified other regions in the sgRNA where mismatches lead to weak or no substrate binding. We found that out of the 32 defining SNVs reported across all the three lineages 37 , 10 sites were targetable by FnCas9 ( Figure 1B , C, Supplementary Table   1 ). Critically, the N501Y mutation present across all the lineages falls within this category 39 . This mutation is present in the receptor-binding domain of the virus and is the subject of numerous studies analyzing the efficacy of vaccines against the mutated form of the virus 40-42 . Owing to its prevalence as a shared marker for mutated lineages, we took this SNV further for developing the diagnostic assay.

We designed primer pairs surrounding the N501Y mutation after analyzing the mutational spectrum in SARS-CoV2 strains obtained from the publicly available sequencing data 5,37,43 . Additionally, we ensured that no regions from human or non-human transcriptome shared significant homology to the sites to prevent any non-specific amplification during the reverse transcription PCR (RT-PCR) reaction ( Figure 1D ). Our earlier FELUDA design validated on a large number of patient samples used an S-gene sgRNA for detecting the presence of SARS-CoV2 inpatient samples 25 . We reasoned that including the same sgRNA for detecting the S gene region which is in the vicinity of the N501Y variant would serve as an internal positive control for the presence of the SARS-CoV2 virus in the sample. To this end, we ensured that all amplicons contained both the sites of the N501Y targeting sgRNA as well as the earlier FELUDA S-gene sgRNA.

We next tested the N501Y sgRNA containing the mismatch at PAM proximal 6th position to selectively bind and cleave the mutant substrate, while not affecting the WT substrate due to mismatch at PAM proximal 2nd and 6th positions. We found that FnCas9 was able to successfully cleave the substrate containing the N501Y mutation while the WT . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250900 doi: medRxiv preprint sequence was not cleaved (Figure 2A ). Importantly, this leads to a distinct pattern on agarose gel that can distinguish the two variants. We established that this approach for variant identification can be performed using a stand-alone or portable electrophoresis apparatus leading to a turnaround time of about 1.5 h from RNA to read-out and can readily replace the current sequencing-based discrimination of variants for rapid diagnosis (Figure 2A ).

Since the CoV2 genome has already undergone multiple mutations, and there could be more mutations of concern occurring in the recent future, we validated RAY on another mutation T716I using the same design principles. Remarkably, T716I was also successfully distinguished using RAY ( Figure 2A ). All together, RAY design parameters are consistent across different mutations, and the pipeline can be seamlessly adapted for novel mutations that might emerge in the nCoV2 genome.

The portable electrophoresis based identification of the N501Y(A23063T) mutation can be adapted for COVID-19 detection under laboratory conditions. However, dye-based systems have low sensitivity and will undergo limitations when viral load is not high. We reasoned that for RAY to detect and diagnose variants, we need to adapt the detection to a more sensitive readout. Since the FELUDA platform on a lateral flow strip can detect COVID-19 positive individuals across all ranges of Ct values, we developed a pipeline for adapting RAY on a paper strip.

To generate a visually distinctive signal between WT and mutant variants, we modified our previous FELUDA protocol to identify SNV accurately in the sample 25 . Firstly, we performed a single-step reverse transcription PCR to generate a biotin-labeled amplified product that can be detected by a single sgRNA (S-gene) if the sample is WT and by both sgRNAs (S-gene and N501Y) if the sample contains the N501Y variant. A single amplicon for both the sgRNAs ensures that there is no PCR bias in detecting the two regions by CRISPRDx from the same sample. Secondly, we eliminated one of the biotin label . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250900 doi: medRxiv preprint primers (from the FELUDA reaction) to reduce the chances of background signal due to non-specific interactions of the unused biotin primers with the streptavidin. Thirdly, we made modifications at the level of amplicon length, PCR conditions, and RNP concentration to generate the most optimal protocol that can produce a clear discernible signal on a commercially available paper strip ( Figure 2B , Methods). To validate the reproducibility of this method, we took mutant and WT substrates, and performed RAY ten times, and were able to successfully distinguish them on every occasion ( Figure 2C ). Ct values by the smart-phone based application TOPSE to generate backgroundcorrected intensity values. Notably, for every sample, the whole process from RNA to read-out can be completed in ~75 min, highlighting the efficacy of assay for the quick identification of individuals carrying the variant ( Figure 3B ).

Currently, deep-sequencing of patient samples is routinely being followed by health authorities in various countries to track and isolate cases containing the CoV2 variants [21] [22] [23] [24] . The accuracy of variant calling in any sequencing platform is dependent on the very high quality and coverage of reads to the reference genome. Since the process from sample to sequence consists of multiple steps, low viral titre can be missed out during sequencing assays reducing the overall sensitivity. The RAY pipeline uses an . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250900 doi: medRxiv preprint amplification step and enzymatic binding assay and is reproducible across all the viral titre. Therefore can detect samples across all ranges of Ct values.

The main advantage of sequencing COVID-19 samples is the generation of cumulative information about all mutations co-existing in a given variant 44,,45 . This information is valuable to track and trace how lineages evolve and has led to the identification of mutations in the first place. However, routine sequencing of patient samples for surveillance or First point detection is fraught with issues, such as cost, logistics, and turnaround times. A typical deep sequencing cost per sample is several orders of magnitude more than RAY (which costs less than 10 USD per sample) and the minimum turnaround time for sequencing is 36 hours (Supplementary Table 2 ). Importantly, sequencing runs are generally done on pooled samples to save on cost, workforce, and machine time, all of which necessitate the advent of alternate solutions that can identify variants through a simple pipeline. RAY,-on the contrary-is scalable to any number of samples at a given time.

RAY gives the advantage of rapid identification of a conserved mutation and is useful for diagnosis and surveillance. Since its readout is on a paper strip where one mutation can be detected at a time, identifying multiple mutations will require performing several RAY reactions. Additionally, RAY is not suited for identifying new variants that have emerged in a sample-unlike sequencing. However, the universality of the sgRNA design by which FnCas9 can discriminate between mutations makes it possible to multiplex the identification of several variants from the same sample.

Sequencing generates a large amount of data and requires physical storage and highperformance computing methodologies to record, analyze and interpret the data 44,45 . In addition, dedicated personnel with a significant understanding of sequence analysis and programming skills are necessary for identifying variants within reads generated from a sample. In contrast, RAY uses a visual readout on a paper strip leading to a binary decision about the sample. That has the advantage of rapid screening, particularly at the point of care settings. To facilitate electronic recording and analysis of the readout TOPSE, a mobile app described in our earlier study can be used in combination with RAY 25 . In addition to background correction, it also enables an automated decisionmaking process to assist the user's visual interpretation 25 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250900 doi: medRxiv preprint RAY has the scope of improvement in both performance and robustness. The use of chemically modified crRNAs would lead to greater stability of reaction components and higher band intensities, particularly for samples with high Ct values. Similarly, as shown earlier for FELUDA, a fluorescence-based readout can facilitate multiplexing several samples in a single run. This is useful for scaling up of testing, particularly where rapid decision making is required.

In this study, we report the development of a CRISPR diagnostic platform for detecting variants in SARS CoV2. Considering the rise and spread of mutated lineages of the virus in multiple countries, it is imperative to develop technologies that can quickly and accurately detect these variants. Since the first generation vaccines against SARS CoV2 have been developed against the parent strain, careful assessment of the variant lineages and their response to the vaccine will become imperative in the coming months of the pandemic 46-48 . Novel variants, particularly those correlated with adverse disease manifestation, need to be controlled so that these do not spread rampantly across populations. Testing and isolating them will thus continue to be at the forefront of disease control measures.

The study was designed to evaluate the efficacy of RAY on clinical samples. The intent of the study was to develop a robust CRISPR diagnostic that can perform with high accuracy for variant detection at significantly low cost and time taken for detection. For the N501Y detection using FELUDA, SARS CoV2 and control RNA samples were received from the diagnostic laboratory at CSIR-Institute of Genomics and Integrative Biology, where the clinical diagnosis was done before the left-over samples were used in this study.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250900 doi: medRxiv preprint

A list of all oligos (Merck) used in the study can be found in Supplementary Table 3 . 

All 32 mutations defining B.1.1.7 and B.1.351/501Y-V2 lineages were extracted from Pangolin 37,49 . Further by keeping these mutations at 2nd/6th/16th/19th bp upstream to PAM (NGG) in SARS-CoV2 we were able to target 10 mutations. Next, these mutations were incorporated into the crRNA sequence followed by a random mismatch at corresponding 6th/2nd/19th/16th position. Primers flanking these crRNAs were designed using Primer3plus python library 50 . Finally, Primers were investigated for off-targets on representative bacterial genome database (NCBI), virus genome database (NCBI) and human genome/transcriptome (GENCODE GRCh38) 51-53 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250900 doi: medRxiv preprint Sequences containing WT and Mutant were reverse transcribed, and amplified using primers with/without 5' biotinylation from SARS-CoV2 Viral RNA enriched samples.

Purified PCR amplicons containing WT and Mutant sequences were used as substrate in in vitro cleavage assays, as optimized in our previous studies. Substrate amplicons were treated with reconstituted RNP complex (100nM) in a reaction buffer (20 mM HEPES, pH7.5, 150mM KCl, 1mM DTT, 10% glycerol, 10mM MgCl2) at 37°C for 10 minutes, and cleaved products were visualized on a 2 % agarose gel.

A region from the SARS-CoV2 S gene containing N501Y/T716I mutations was reverse transcribed and amplified using a single end 5' biotin-labeled primers.

In vitro transcription of sgRNAs/crRNAs was done using MegaScript T7 Transcription kit 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The individuals with UK travel history between December 2020-January 2021, who were found to be RT-PCR positive for SARS-CoV2, were sequenced to determine whether it was a UK variant (20I/501Y.V1) or non-UK variant. With a low number of samples arriving each day in the lab and with quick turnaround time for reporting, Nanopore sequencing was undertaken.

In brief, 100ng total RNA was used for double-stranded cDNA synthesis by using . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250900 doi: medRxiv preprint PTC_9096_v109revE_06Feb2020). Sequencing in sets of 24 barcoded samples was performed on MinION Mk1B platform by ONT.

The ARTIC end-to-end pipeline was used for the analysis of MinION raw fast5 files up to the variant calling. Raw fast5 files of samples were basecalled and demultiplexed using Guppy basecaller that uses the base calling algorithms of Oxford Nanopore Technologies (https://community.nanoporetech.com) with phred quality cut-off score >7 on GPU-linux accelerated computing machine. Reads having phred quality scores less than 7 were discarded to filter the low-quality reads. The resulting demultiplexed fastq were 

The present study was approved by the Ethics Committee, Institute of Genomics and Integrative Biology, New Delhi. A patent application has been filed in relation to this work.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250900 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250900 doi: medRxiv preprint 

SARS-CoV-2 and coronavirus disease 2019: what we know so far

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Geographic and genomic distribution of SARS-CoV-2 mutations

Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01 (PDF)

Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

Coronavirus pandemic (COVID-19)

Real-time PCR in virology

Assay techniques and test development for COVID-19 diagnosis

Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus

Should RT-PCR be considered a gold standard in the diagnosis of Covid-19?

Presence of mismatches between diagnostic PCR assays and coronavirus SARS-CoV-2 genome

Considerations for diagnostic COVID-19 tests

High-density amplicon sequencing identifies community spread and ongoing evolution of SARS-CoV-2 in the Southern United States

Multiple approaches for massively parallel sequencing of SARS-CoV-2 genomes directly from clinical samples

High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing

Rapid, accurate, nucleobase detection using FnCas9

Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA

Ultrasensitive and visual detection of SARS-CoV-2 using all-inone dual CRISPR-Cas12a assay

An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12

CRISPR-Cas12-based detection of SARS-CoV-2

We thank all members of Chakraborty and Maiti labs for helpful discussions and valuable